眼科領域におけるNY-198の臨床的・基礎的検討

DOI

書誌事項

タイトル別名
  • BASIC AND CLINICAL STUDIES ON NY-198 IN OPHTHALMOLOGY

抄録

We performed basic and clinical studies on NY-198, a new quinoline derivative for oral use, in the field of ophthalmology.<BR>1) NY-198 was administered orally in a daily dose of 300mg or 600mg to 17 patients with various eye infections, including hordeolum 6, acute dacryocystitis 2, meibomitis 7, corneal ulcer 1, and lid abscess 1. Clinical results were excellent in 10, good in 6, and fair in 1, the total efficacy rate being 94.4%.<BR>2) We measured NY-198 concentrations in both serum and tear fluid 0.5, 1.0, 2.0, 3.0, 4.0, and 6.0 hours after a single oral dose of 200mg. The average peak serum and tear levels were 1.25μg/ml±0.14 and 0.98μg/ml±0.27 at 2 h after treatment. This tear level was considered effective in external eye infections (meibomitis, hordeolum, dacryocystitis, etc.) caused byS. aureus.<BR>3) No side-effects or abnormal clinical laboratory findings due to NY-198 were observed, with the exception of stomach-ache in one patient.

収録刊行物

詳細情報 詳細情報について

問題の指摘

ページトップへ